ABSTRACT
In brachioradial pruritus and notalgia paraesthetica, the 8% capsaicin patch is a novel and effective, but cost-intense, therapy. Routine data for 44 patients were collected 6 months retrospectively and prospectively to first patch application. The cost to health insurance and the patient, and patient-reported outcomes were analysed (visual analogue scale, numerical rating scale, verbal rating scale for pruritus symptoms, Dermatological Life Quality Index, and Patient Benefit Index). Mean inpatient treatment costs were reduced by 212.31, and mean outpatient treatment and medication costs by 100.74 per patient (p.p.). However, these reductions did not offset the high cost of the patch itself (767.02 p.p.); thus the total cost to health insurance increased by 453.97 p.p. (p ≤ 0.01). The additional costs of therapy to the patient decreased by 441.06, thus the overall cost p.p. remained approximately the same (3,306.03 vs. 3,318.94). Capsaicin patch therapy resulted in reduced pruritus, improved quality of life and greater patient benefit, thus long-term cost-efficiency analyses are necessary.
